IPH5301, A Differentiated Therapeutic Antibody Targeting Membrance & Soluble CD73, Unleash Anti-Tumor Immune Response In Combination With Cancer Therapies

Time: 3:45 pm
day: Day Two


• Demonstrating IPH5301 differentiated Mode of Action on both membrane and soluble CD73, resulting in optimal restoration of immune response

• Highlighting preclinical safety and activity for IPH5301 in animal models

• Discussing First in Human phase 1 trial